The predictive value of PgR and HER-2 for response to primary systemic chemotherapy in inflammatory breast cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

The predictive value of PgR and HER-2 for response to primary systemic chemotherapy in inflammatory breast cancer

Published:2008-08 Issue:4 Volume:13 Page:340-344
ISSN:1341-9625
Container-title:International Journal of Clinical Oncology
language:en
Short-container-title:Int J Clin Oncol

Author:

Nogi Hiroko,Kobayashi Tadashi,Tabei Isao,Kawase Kazumi,Toriumi Yasuo,Suzuki Masafumi,Morikawa Toshiaki,Uchida Ken

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Hematology,General Medicine,Surgery

Link

http://link.springer.com/content/pdf/10.1007/s10147-008-0760-8.pdf

Reference20 articles.

1. Hance KW, Anderson WF, Devesa SS, et al. (2005) Trends in inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program at the National Cancer Institute. J Natl Cancer Inst 97:966–975

2. Sawaki M, Ito Y, Akiyama F, et al. (2006) High prevalence of HER-2/neu and p53 overexpression in inflammatory breast cancer. Breast Cancer 13:172–178

3. Haagensen CD (1971) Inflammatory carcinoma. Diseases of the breast, 2nd edn. W. B. Saunders, Philadelphia, PA, pp 576–584

4. Cristofanilli M, Buzdar AU, Hortobagyi GN (2003) Update on the management of inflammatory breast cancer. Oncologist 8:141–148

5. Therasse P, Arbuck SG, Eisenhauer EA, et al. (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205–216

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Nanodrug Formed by Coassembly of Dual Anticancer Drugs to Inhibit Cancer Cell Drug Resistance;ACS Applied Materials & Interfaces;2015-08-19

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3